Abstract GABA A receptors (GABA A Rs) are Cl --selective ligand-gated ion channels that mediate both fast synaptic inhibition and persistent tonic inhibition in the CNS. The receptor is composed of subunits that affect biophysical and pharmacological properties of the channel. A growing number of studies have examined copy number variations, mutations, and polymorphisms in genes encoding GABA A R subunits and found that changes in subunit function and expression are linked to a variety of neurological disorders. GABA A Rs are targets for a wide range of pharmaceutical agents including benzodiazepines, barbiturates, general anesthetics, and neurosteroids. It remains to be fully determined how genetic variations in GABA A subunits affect clinical pharmacology. Conversely, there is growing interest in the use of GABAergic drugs to treat disorders with an etiology arising from genetic variations in GABA A subunits.
Introduction
The GABA A receptor (GABA A R) belongs to a superfamily of ligand-gated ion channels which includes the nicotinic acetylcholine (nACh) receptor, glycine receptor, serotonin type III (5-HT 3 ) receptor, and the zinc activated channel [1] . Members of this superfamily are pentameric heterooligomers, the subunits of which have a common structure encompassing a large extracellular N-terminal domain that contains the neurotransmitter binding pocket, four transmembrane domains (TM1-4), and a major intracellular domain between TM3 and TM4 [1] . The five subunits form a ring-like structure with a central, ion-conducting pore with TM2 lining the pore.
The 19 subunits of the GABA A R family fall into several subunit classes, with each subunit having different temporal and spatial expression throughout the CNS. The subunit composition of GABA A Rs can alter the biophysical and pharmacological characteristics of the receptor. The genes for the subunits form chromosomal clusters: chromosome 4p12 (a2, a4, b1, and c1); chromosome 5q31-q35 (a1, a6, b2, c2, and p); chromosome 6q13-q16.3 (q1, and q2); chromosome 15q11.2-q12 (a5, b3, and c3); and chromosome Xq28 (a3, e, and h). The genes for q3, and d are on chromosomes 3q11.2 and 1p36.3, respectively. The clustering of the subunit genes is believed to help coordinate gene expression [2] .
Benzodiazepine-sensitive receptor subtypes are composed of a1-3, bn, and cn subunits [3] [4] [5] . These types of GABA A Rs are typically located at the synapse and are activated by brief (1-2 ms) pulses of GABA from presynaptic GABA vesicle release. The released GABA is rapidly removed by GABA transporters (GAT1-3) located in the membranes of neurons and glia, thus limiting GABA's actions in the synapse. The GABA-mediated current is transient as a result of this rapid rise and fall in synaptic GABA levels, and inhibition is termed phasic inhibition. Extrasynaptic GABA A Rs are commonly composed of a4-6, bn, and either c2 or d subunits, although in some regions of the brain other subunit combinations, including heteromeric ab receptors, maybe found [6, 7] . Little is known about the synaptic or extrasynaptic location of c1 or c3 subunits. These extrasynaptic GABA A Rs are activated by ambient GABA to produce a persistent or tonic current (discussed by Houston et al. [8] ). Extrasynaptic receptors are characterized by a high GABA potency, enabling them to detect the low ambient GABA concentration in the extracellular space [6, 7, [9] [10] [11] . Although the amplitude of tonic current is smaller than that of synaptic current, the persistent nature of tonic current enables greater charge transfer over time. This tonic inhibition significantly affects neuronal and circuit excitability [12] . Ambient GABA originates from several sources, including synaptic spillover, release from glia, or release from neurogliaform cells [13, 14] . In addition to activation of GABA A Rs from ambient GABA, some GABA A Rs have a higher probability to transition from a The ion-conducting pore of GABA A Rs is selective for chloride anions (Cl -), which flow down their electrochemical gradient. In adult mammalian neurons this flow tends to be inward, hence hyperpolarizing the neuron, taking the membrane potential further away from its threshold potential. The low intracellular Cl -concentration in an adult neuron is created by efficient potassium chloride cotransporters (KCC-2). A common misconception is that KCC-2 function and surface expression are static in adult neurons, and hence, GABA A -mediated responses are always hyperpolarizing. Recent results have revealed that neuronal excitation can rapidly alter the phosphorylated state of KCC-2 and hence the rate of ion transport and the cell surface stability of KCC-2, leading to a depolarizing GABA A -mediated response [17, 18] . Hence, KCC-2 function can be plastic, depending on the activity of a circuit, and the altered Cl -homeostasis would have a further effect on neuronal excitability. In several neurological disorders, for example epilepsy, ischemia, and chronic pain, disruption of KCC-2 function has been described which would lead to a perturbed Cl -homeostasis and GABA-mediated inhibition [19] .
Genetics GABA A Rs, as mentioned above, are critical for setting the inhibitory tone and for affecting the precise timing of neuronal firing in networks. It is of no surprise that abnormalities in the expression and function of GABA A Rs will have a pathological phenotype [20] . Many copynumber variations (CNV), mutations, and polymorphisms in genes encoding GABA A R subunits have been described. The biophysical and pharmacological properties of GABA A Rs are substantially affected by the type of subunit which is expressed in the receptor. Any alterations in the expression of subunits with CNVs and changes in subunit structure as a result of mutations and polymorphisms could affect inhibitory signaling and pharmacological responses, complicating therapy and responses to drugs. These changes can also have far-reaching consequences on other proteins; the physiological state of the neuron could be changed such that other signal pathways, downstream of the Cl -flux, change the expression of other genes [21] . Both phasic and tonic inhibition are sensitive to changes and have been described for several disease states. Alterations of the efficacy of tonic inhibition have been strongly implicated in premenstrual disorder, post-partum depression, post-partum seizures, catalepsy, and temporal lobe epilepsy [22] [23] [24] . Deficits in tonic inhibition are also found in Fragile X syndrome, suggesting that such inhibition is important for cognitive function [25, 26] . The changes to tonic inhibition in these conditions can be brought about by several factors (on their own or in combination), for example changes in functional receptors, changes in the concentration of agonist, or changes in concentration of neurosteroids that greatly affect tonic inhibition.
In recent years it has emerged that de-novo mutations are crucially involved in epilepsies and neurodevelopmental disorders including autism, intellectual disability, and schizophrenia. Mutations in genes encoding for GABA A R subunits are a common occurrence in these disorders. A recent study found a de-novo mutation in the gene for the GABA A R b3 subunit that had significant occurrence as a single-gene cause of epileptic encephalopathies [27 • ]. The study also observed de-novo mutations in the gene for the GABA A R a1 subunit. Neurodevelopmental disorders occurred among patients with a CNV in chromosome 4q12-13 resulting in the duplication of the genes for GABA A subunits a2, a4, b1, and c1 [28] . Similarly, maternal duplications of chromosome 15q11-13, which includes genes for the a5, b3, and c3 subunits, have been linked to autism spectrum disorders [29] .
Idiopathic epilepsy syndromes make up *50 % of epilepsies and several GABA A subunit mutations (usually inherited but also de-novo mutations) have been associated with these epilepsies (reviewed in depth by Macdonald et al. [30] ). A mutation in the N-terminal of the b3 subunit (G32R) is associated with childhood absence epilepsy [31 • ]. The mutation leads to an increase in the glycosylation of the b3 subunit, which alters the subunit assembly of mature GABA A Rs and reduces the gating of the receptor to an open state. For subunit assembly, the mutation results in a strong salt bridge forming between b3 subunits. Interestingly, the authors suggested that the mutation would result in a change from abc to more receptors composed of binary a1b3 and homomeric b3 subunits. The resulting cells expressing these receptors would be likely to change their electrical activity and pharmacological properties, as homomeric b3 receptors are not activated by GABA but can be directly activated by neurosteroids and propofol [32] .
Expression of GABA A subunits may also be affected by mutations in other genes. Fragile X mental retardation protein (FMRP) is an RNA binding protein responsible for transport and translational regulation of several proteins [33] . Fragile X syndrome occurs with a CGG repeat mutation in the Fmr1 gene that encodes FMRP [34] , leading to reduced expression of FMRP in Fragile X and other autism spectrum disorders [35] . One target of FMRP is the GABA A d subunit mRNA [36] . With the Fmr1 gene mutation, reduced d subunit expression and reduced tonic inhibition result in an imbalance of the inhibitory-toexcitatory ratio. Interestingly, FMRP is also downregulated in schizophrenia, bipolar disorder, and major depression [37, 38] , neurological conditions in which changes in GABA A R expression and function are known to occur [20, 37, 39] .
Clinical Pharmacology
Because GABA is the major inhibitory neurotransmitter in the adult CNS, GABA A Rs are crucially important in the excitability of neurons. Many clinically relevant compounds have been shown to interact with GABA A Rs and in so doing potentiate the GABA-evoked Cl -current. Such compounds include benzodiazepines [40] , the anesthetic barbiturates [41] , and propofol [42] . Other relevant agents that positively modulate the receptor include the anesthetic synthetic steroid, alphaxalone [43] , and the progesterone and deoxycorticosterone metabolites, allopregnanolone and THDOC [44] . These compounds are used clinically as anxiolytics, anticonvulsants, and sedative and/or hypnotic and/or anesthetic agents.
Benzodiazepines
Benzodiazepines are among the most widely used pharmaceutical agents. The high frequency of clinical use is because of their anxiolytic, anticonvulsant, amnestic, muscle relaxant, and sedative-hypnotic properties [3, 45, 46] . Unfortunately, benzodiazepines also cause unwanted side effects, for example excessive (or unwanted) sedation, tolerance, dependence, and abuse. The benzodiazepine binding site on GABA A Rs is well documented. Benzodiazepine-sensitive GABA A Rs are formed from an a subunit (a1, a2, a3, or a5) with a b subunit and a c subunit in 2:2:1 stoichiometry. The benzodiazepine binding site is at the subunit interface between the a and c subunits [47] .
Whereas early benzodiazepines were not selective for any particular a subunit, newer benzodiazepine compounds have been produced that do have selectivity for the a subunit, providing insight into the subunit specificity of benzodiazepine behavioral profiles [3] . In addition, transgenic mice that have had their benzodiazepine-sensitive a subunit mutated into a benzodiazepine-insensitive one have provided the unique ability to test the behavioral properties of benzodiazepines. As a result of using these transgenic techniques it is now known that benzodiazepine-enhancing a1 subunits containing GABA A Rs mediate sedative effects whereas anxiolysis and myorelaxant actions are mediated through the a2 and a3-containing GABA A Rs. Benzodiazepines' ability to cause amnesia is mediated through GABA A Rs containing the a5 subunit [48, 49] .
Benzodiazepines such as diazepam and lorazepam are the first treatment for status epilepticus (SE). Refractory SE occurs when SE continues despite benzodiazepine treatment; hypnotic agents, for example volatile anesthetics, barbiturates, and propofol, are then used [19, 50] . It has been suggested that internalized synaptic GABA A Rs cause this resistance to benzodiazepine during SE, but recently we have demonstrated, by use of an in-vitro model, that benzodiazepine resistance can occur because of impaired KCC-2 function leading to accumulation of intracellular Cl -and depolarizing GABA A R-mediated responses. Interesting even though GABA A R-mediated responses were depolarizing, propofol was still able to inhibit action potentials because it predominantly enhanced the tonic current, electrically shunting membrane conductance [51 • ].
General Anesthetics
General anesthetics have widely heterogeneous structures yet during the early 1990s it was demonstrated that most anesthetics at clinically relevant concentrations enhance the effects of GABA on GABA A Rs. At higher concentrations, some anesthetics, particularly the i.v. anesthetics propofol, etomidate, and the barbiturates, could directly activate GABA A Rs in the absence of GABA. This direct activation by anesthetics distinguished them from benzodiazepines which are not GABAmimetic.
After the early observations of GABA A R modulation by general anesthetics, much effort was devoted to investigation of which subunits, and in particular which residues, were important to anesthetic properties. Site-directed mutagenesis studies produced several residues of interest, particularly in the TM regions of the a and b subunits, for both volatile and i.v. anesthetics [52] . The mutagenesis studies naturally led to the generation of transgenic animals to test the in-vivo effects of these residues.
After the discovery that a residue in the b2 and b3 subunits was important for modulation of GABA-evoked currents by i.v. anesthetics, transgenic mice were generated carrying b2(N265S) and b3(N265 M) mutations that render the GABA A R carrying them insensitive to the enhancing actions of etomidate and propofol [53, 54] . Investigation of the anesthetic endpoints of etomidate and propofol in these transgenic mice revealed that loss of consciousness can be mediated purely through b3-containing GABA A Rs, whereas the b2 subunit mediates the sedative properties of anesthetics.
Mutated receptor subunits have provided us with much information, but one problem with this technique is the mutation itself can cause conformational changes that alter the interaction with the anesthetic, or prevent the conformational change needed for the allosteric enhancement when the anesthetic has bound to the receptor. Photoaffinity labeling uses analogues of general anesthetics that photo-react when exposed to light of a specific wavelength and, if the anesthetic has already bound to the receptor, will label the residue in contact with the anesthetic. By using this method, azietomidate photo-affinity labeling identified a methionine in TM1 of the a1 subunit (M236) and a methionine in TM3 of the b3 subunit (M286) [55] . Use of homology models revealed a1-M236 and b3-M286 face each other, thus forming a binding site between the two subunits. Recently, a propofol analogue was used to photolabel a site in the b3 subunit of both a1b3 heteromeric and b3 homomeric receptors. Histidine 267 lies near the extracellular end of TM2 [56] . Another recent study examined a photoreactive barbiturate which labeled a1 subunit TM3 at A296 and Y294, c2 subunit TM3 at S301, and b3 subunit TM1 at methionine 227. These sites are located on the extracellular side of the channel at subunit interfaces [57] . It seems, therefore, that the structurally diverse anesthetics bind at different sites within the channel to allosterically modulate the channel.
Neurosteroids
Neurosteroids are synthesized de novo in the brain from cholesterol or from steroid hormone precursors. Increasing the concentration of neurosteroids in the CNS causes anxiolysis, sedation, anticonvulsant action, and anesthesia and reduces depressive-like behavior [58] . Dysregulation of neurosteroid signaling is associated with neurological and psychiatric disorders which include traumatic brain injury, post-traumatic disorder, premenstrual dysphoric disorder, panic disorder, depression, schizophrenia, and bipolar disorder [59] . Neurosteroids exert most of their actions by allosterically enhancing the activity of GABA on GABA A Rs. At low nanomolar concentrations they potentiate submaximum GABA-dependent currents; at a single channel level neurosteroids increase the open time and frequency of opening of the channel [60] . At micromolar concentrations, they directly activate GABA A Rs in the absence of GABA [61, 62] . This direct activation property has largely been ignored because larger, nonphysiological, concentrations are needed to see this direct gating effect. However, it has been reported that neurosteroids can slowly directly activate GABA A Rs at high nanomolar concentrations via accumulation in the membrane where they are able to access an activation site [63] .
Neurosteroids have been shown to bind GABA A Rs at an allosteric site distinct from that of GABA, benzodiazepines, or barbiturates [46, 64, 65] . Hosie et al., identified residues located within the transmembrane domain of GABA A R a and b subunits that are critical for the direct activation (a1-6; threonine 236, b1-3; tyrosine 284) and allosteric potentiation (a1-6 asparagine 407, and a1-6 glutamine 241) by neurosteroids [66] [67] [68] . Accordingly, mutation of glutamine 241 (Q241) within the a1-6 subunits, prevents allosteric potentiation of GABA A R composed of abc and abd subunits by neurosteroids [66, 67] . In photo-affinity labeling experiments using a photolabeling neurosteroid analog and homomeric b3 receptors, the only residue labeled was phenylalanine 301 in TM3 of the b3 subunit [69] .
Neurosteroids are increasingly being thought of as therapeutic agents for numerous conditions arising from anxiety, traumatic brain injury, epilepsy, and neurodevelopment [70] . Ganaxolone, a synthetic analog of allopregnanolone, a metabolite of progesterone, is currently showing great promise in clinical trials for use in pediatric and adult cases of seizure disorders [71] .
Conclusion
Mutations, CNVs, and polymorphisms of GABA A R subunits have been linked to numerous neurodevelopment disorders and epilepsies. It remains unknown how these modifications to the genes of subunits change the properties of the mature protein and change pharmacological responses to the numerous compounds that target GABA A Rs. Altered GABA A R function or expression is an obvious therapeutic target to counteract these changes but we need to better understand the changes that occur at a cellular, circuit, and organism level.
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